Clinical Efficacy Analysis of Shugan Jieyu Capsules Combined with Esci-talopram in the Treatment of Refractory Depression
Objective To explore the clinical efficacy of Shugan Jieyu Capsules combined with escitalopram in the treatment of refractory depression.Methods Ninety-eight patients with refractory depression admitted to the Depart-ment of Psychiatry of Changshu Third People's Hospital from August 2022 to August 2023 were non-randomly se-lected as the study subjects,and were divided into two groups according to treatment methods,with forty-nine cases in each group.The control group was treated with escitalopram oxalate tablets,and the observation group was treated with Shugan Jieyu Capsules combined with escitalopram oxalate tablets.The two groups were compared in terms of brain-derived neurotrophic factor(BDNF),substance P(SP),efficacy and adverse reactions.Results After treatment,the BDNF level of the observation group was higher than that of the control group,and the SP level was lower than that of the control group,and the differences were statistically significant(both P<0.05).The total effective rate of the ob-servation group was 95.92%(47/49),which was higher than 81.63%(40/49)of the control group,and the difference was statistically significant(χ2=5.018,P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The clinical treatment of refractory depression is more effective and has a higher safety profile with the use of liver relief capsules combined with escitalopram.
NETL
NSTL
万方数据
